J Korean Neurosurg Soc.  2018 May;61(3):312-318. 10.3340/jkns.2018.0003.

Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era

• Jung TY
• Jung S
• Kook H
• Baek HJ

• KMID: 2417356
• DOI: http://doi.org/10.3340/jkns.2018.0003

Abstract

Surgery and radiotherapy are mainstays of treatment for ependymomas (EPNs). Recent molecular subgrouping could be superior to histopathological grading for predicting the prognosis of patients with EPNs. Gross total resection is an effective treatment approach regardless of its locations or pathologic grades. Adjuvant therapeutic strategies could be decided based on molecular subgrouping with risk-stratification. Information of histologic-molecular biology is now providing clues to therapeutic insights.

Keyword

Ependymoma; Biology; Molecular medicine; Prognosis; Therapeutics

MeSH Terms

Biology
Ependymoma*
Global Health*
Humans
Molecular Medicine
Prognosis
Radiotherapy
World Health Organization*

Reference

References

1. Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM, Yock TI, Tarbell NJ, et al. Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol. 115:411–419. 2013.

2. Archer TC, Pomeroy SL. Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell. 20:133–134. 2011.

3. Benesch M, Weber-Mzell D, Gerber NU, von Hoff K, Deinlein F, Krauss J, et al. Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr. 6:137–144. 2010.

4. Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer. 104:143–148. 2005.

5. Chai YH, Jung S, Lee JK, Kim IY, Jang WY, Moon KS, et al. Ependymomas: prognostic factors and outcome analysis in a retrospective series of 33 patients. Brain Tumor Res Treat. 5:70–76. 2017.

6. Chamberlain MC, Johnston SK. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer. 115:4775–4782. 2009.

7. DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol. 123:85–91. 2015.

8. Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 10:7. 2011.

9. Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, et al. A phase II study of lapatinib and dose dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial. Neuro Oncol. 16(suppl_5):v13. 2014.

10. Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, et al. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro Oncol. 19:1183–1194. 2017.

11. Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ. Chemotherapy for advanced CNS ependymoma. J Neurooncol. 45:61–67. 1999.

12. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 28:3182–3190. 2010.

13. Leeper H, Felicella MM, Walbert T. Recent advances in the classification and treatment of ependymomas. Curr Treat Options Oncol. 18:55. 2017.

14. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131:803–820. 2016.

15. Mack SC, Taylor MD. Put away your microscopes: the ependymoma molecular era has begun. Curr Opin Oncol. 29:443–447. 2017.

16. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506:445–450. 2014.

17. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys. 61:387–391. 2005.

18. Massimino M, Solero CL, Garrè ML, Biassoni V, Cama A, Genitori L, et al. Second-look surgery for ependymoma: the Italian experience. J Neurosurg Pediatr. 8:246–250. 2011.

19. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 10:258–266. 2009.

20. Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol. 12:976–984. 2010.

21. Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M, et al. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol. 14:1346–1356. 2012.

22. Nakamura T, Fukuoka K, Ikeda J, Yoshitomi M, Udaka N, Tanoshima R, et al. Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. Brain Tumor Pathol. 34:160–164. 2017.

23. Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 133:5–12. 2017.

24. Pajtler KW, Pfister SM, Kool M. Molecular dissection of ependymomas. Oncoscience. 2:827–828. 2015.

25. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 27:728–743. 2015.

26. Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 134:705–714. 2017.

27. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature. 506:451–455. 2014.

28. Paulino AC. The local field in infratentorial ependymoma: does the entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys. 49:757–761. 2001.

29. Paulino AC, Wen BC. The significance of radiotherapy treatment duration in intracranial ependymoma. Int J Radiat Oncol Biol Phys. 47:585–589. 2000.

30. Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol. 34:2468–2477. 2016.

31. Rudà R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 18:261–268. 2016.

32. Venkatramani R, Dhall G, Patel M, Grimm J, Hawkins C, McComb G, et al. Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer. 58:380–383. 2012.

33. Venkatramani R, Ji L, Lasky J, Haley K, Judkins A, Zhou S, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neurooncol. 113:285–291. 2013.

34. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 17:440–447. 2015.

35. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 20:143–157. 2011.